查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2093203

更年期市場－2026-2032年全球市場預測

Menopause Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，更年期市場規模將達到 246.9 億美元，複合年成長率為 7.58%。

主要市場統計數據
基準年 2025 148億美元
預計年份：2026年 158.8億美元
預測年份 2032 246.9億美元
複合年成長率 (%) 7.58%

更年期執行摘要：在中年保健連續體中促進實證女性健康

更年期正從以往被忽視的生命階段轉變為涵蓋女性健康、臨床照護、職場福祉、數位健康和​​消費者健康等領域的重點領域。這項轉變通常發生在45至55歲之間，臨床上定義為連續12個月無月經，但閉經可能提前數年開始，並常伴隨血管舒縮症狀、睡眠障礙、泌尿生殖系統綜合症、情緒波動、認知能力下降、骨骼密度降低以及心血管代謝風險變化。由於症狀因個體、種族、合併症、生活方式和醫療保健資源的不同而存在顯著差異，因此在更年期背景下，越來越需要個性化的、循證的支持，而不是千篇一律的干預措施。

更年期格局的改變：從緩解症狀到終身預防保健。

由於人口結構變化、患者權益倡導、臨床醫學現代化以及人們對女性健康差異日益成長的認知，更年期護理領域正在經歷變革性變化。隨著預期壽命的延長，許多女性在閉經會度過相當長的時間，凸顯了預防骨質疏鬆症、心血管疾病、泌尿生殖系統健康、代謝健康和認知功能的重要性。因此，更年期護理正從症狀治療轉向長期健康管理。

人工智慧對更年期照護、個人化和可及性的累積影響。

人工智慧（AI）若能在妥善管治和資料檢驗的前提下應用，正逐步改善更年期護理，提升個人化服務、便捷就醫和臨床決策支援。人工智慧驅動的症狀追蹤器能夠幫助識別潮熱、睡眠障礙、情緒波動、月經、藥物依從性以及生活方式誘因等方面的模式，從而促進患者與臨床醫生之間更有效的溝通。自然語言處理工具也能將複雜的指導轉化為易於理解的教育訊息，進而提升女性的健康素養。然而，醫療專業人員的監督仍然至關重要，以降低資訊誤導的風險。

亞太地區、歐洲、北美、拉丁美洲、非洲和中東的關鍵區域洞察

在亞太地區，人口快速老化、數位醫療的廣泛應用以及關於生育年齡的多元文化價值觀正在重塑更年期護理格局。儘管日本、中國、韓國、澳洲和印度的中年女性對醫療保健服務的需求不斷成長，但擁有高度專業化醫療網路的地區與那些因社會偏見、醫護人員培訓不足或自費支出等原因而難以獲得醫療服務的地區之間，更年期護理路徑存在顯著差異。在亞太地區的某些地區，傳統醫學、營養主導療法和以家庭為中心的決策模式仍然發揮著重要作用，這為循證整合和文化敏感的更年期教育創造了機會。

北約、七國集團、金磚國家、歐盟、東協和海灣合作理事會更年期護理生態系統的關鍵群體分析

北約成員國的醫療保健體系與北美和歐洲的醫療保健體係有顯著重疊，在這些地區，更年期與勞動力韌性、軍人家庭健康、職業福祉以及完善的醫療保健基礎設施中標準化的臨床路徑密切相關。儘管七國集團（G7）國家普遍能夠獲得完善的臨床指南、先進療法、數位健康工具和雇主提供的健康計劃，但農村、低收入、少數族群和老年人群體在醫療資源分配方面仍然存在不平等現象。在這些高所得政策環境下，更年期照護日益被視為提升生活品質和促進勞動參與的重要因素。

針對主要更年期市場和醫療保健系統的關鍵國家/地區特定見解。

中國目前的更年期保健現狀受到人口快速老化、醫院網路擴張、數位醫療普及以及中年女性對慢性病預防日益成長的關注等因素的影響。美國是更年期保健領域最值得關注的國家之一，其特點活性化的患者權益倡導、遠端醫療的引入、雇主福利的整合以及臨床醫生就荷爾蒙療法和非荷爾蒙療法的合理使用進行的持續討論。日本是世界上老化程度最高的國家之一，停經後健康、骨質疏鬆症預防和生活品質管理尤其重要。印度擁有龐大的中年人口，但由於社會偏見、認知度低、農村地區醫療資源匱乏以及其他健康優先事項的競爭，開展基層醫療教育和符合當地文化的宣傳活動至關重要。

為更年期健康、數位醫療和職場健康領域的行業領導者提供實用建議。

產業領導者應優先考慮經臨床檢驗、以患者為中心的更年期解決方案，這些方案應涵蓋從閉經到停經後的整個過程。這些解決方案應包括教育、篩檢、症狀管理、心理健康支持、泌尿生殖系統護理、骨骼健康、降低心血管代謝風險以及長期追蹤。解決方案的設計應提供關於益處、風險、禁忌症和替代方案的透明信息，從而促進醫患協作決策。

更年期產業和醫療保健領域基於證據的調查方法

本執行摘要採用系統化的二手調查方法編寫，重點檢驗且有據可依的資訊來源。研究內容包括同行評審的醫學文獻、臨床實踐指南、公共衛生資料、人口統計出版物、監管資訊、專業學會指南以及與更年期、停經後過渡、停經後健康、血管舒縮症狀、更年期泌尿生殖系統症候群、骨骼健康、心血管風險、心理健康和女性健康公平相關的政府衛生資料。

結論：更年期護理正在向個人化、預防性和綜合性的女性健康發展。

更年期正日益成為女性健康的關鍵領域，它與症狀緩解、預防醫學、職場包容、健康老化和健康公平息息相關。目前，更年期照護模式正朝著個人化方向發展，這種模式充分考慮了症狀負擔、臨床風險、文化背景、醫療服務取得途徑以及病患偏好等方面的差異。基於實證醫學和個人化評估的荷爾蒙療法和非荷爾蒙療法、生活方式調整、數位化健康工具、心理健康支持以及泌尿生殖系統護理，都發揮著至關重要的作用。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 更年期市場：依產品類型分類

  • 荷爾蒙補充療法（HRT）
    • 雌激素-黃體素聯合治療
    • 雌激素療法
    • 黃體素療法
  • 非荷爾蒙療法
    • 抗憂鬱症
      • 西洛普魯姆
      • escitalopram
      • Fluoxetine
    • 植物來源補充劑
    • Gabapentin
    • Pregabalin

第8章 更年期市場：依更年期階段分類

  • 停經
  • 閉經
  • 停經後

第9章：更年期藥物市場：依給藥途徑分類

  • 腸內營養
  • 腸外
  • 外用

第10章：更年期市場：依通路分類

  • 醫院藥房
  • 網路藥房
    • 公司網站
    • 電子商務平台
  • 零售藥房

第11章 更年期市集：按地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第12章 更年期市場：依群體分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第13章 更年期市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第14章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Abbott Laboratories
  • Abbvie Inc.
  • Amgen Inc.
  • Apotex Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Cipla Ltd.
  • Eli Lilly and Company
  • Ferring International Center SA
  • Fervent Pharmaceuticals, LLC
  • Gedeon Richter PLC
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Ipsen Group
  • Merck & Co.Inc.
  • Mithra Pharmaceuticals SA
  • Novartis AG
  • Novo Nordisk A/S
  • Organon & Co
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • TherapeuticsMD Inc.
  • Viatris Inc.
Product Code: MRR-B973EDD5E621

The Menopause Market is projected to grow by USD 24.69 billion at a CAGR of 7.58% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 14.80 billion
Estimated Year [2026] USD 15.88 billion
Forecast Year [2032] USD 24.69 billion
CAGR (%) 7.58%

Menopause Executive Summary: Advancing Evidence-Based Women's Health Across the Midlife Care Continuum

Menopause is moving from an under-addressed life stage to a priority area across women's health, clinical care, workplace wellbeing, digital health, and consumer wellness. The transition typically occurs between ages 45 and 55 and is clinically defined after 12 consecutive months without menstruation, while perimenopause can begin years earlier and is often associated with vasomotor symptoms, sleep disruption, genitourinary syndrome, mood changes, cognitive complaints, bone density decline, and cardiometabolic risk shifts. Because symptoms vary widely by individual, ethnicity, comorbidities, lifestyle, and access to care, the menopause landscape increasingly requires personalized, evidence-based support rather than one-size-fits-all interventions.

Growing public discussion, updated clinical guidelines, and rising employer attention are reshaping how menopause is recognized and managed. Healthcare systems are placing greater emphasis on accurate diagnosis, shared decision-making, nonhormonal and hormonal treatment options, mental health integration, bone and cardiovascular risk assessment, and long-term quality of life. At the same time, digital education platforms, remote consultations, symptom trackers, and pharmacy-led access models are helping reduce stigma and improve continuity of care. For decision-makers, menopause now represents a critical intersection of preventive health, inclusive workforce policy, and patient-centered innovation.

Transformative Shifts in the Menopause Landscape: From Symptom Relief to Lifelong Preventive Care

The menopause landscape is undergoing transformative shifts driven by demographic change, patient advocacy, clinical modernization, and broader recognition of women's health inequities. Longer life expectancy means many women spend a substantial proportion of their lives after menopause, increasing the importance of prevention strategies for osteoporosis, cardiovascular disease, urogenital health, metabolic health, and cognitive wellbeing. This is changing menopause care from episodic symptom treatment to longitudinal health management.

Clinical practice is also evolving. Contemporary guidance emphasizes individualized risk-benefit evaluation for menopausal hormone therapy, appropriate use of nonhormonal therapies for vasomotor symptoms, pelvic floor and genitourinary care, sleep and mental health assessment, and lifestyle interventions such as nutrition, resistance training, smoking cessation, and alcohol moderation. The conversation is becoming more nuanced, recognizing that treatment suitability depends on age, time since menopause, medical history, breast cancer risk, thromboembolic risk, cardiovascular status, and patient preference.

Consumer behavior is shifting as well. Women are increasingly seeking validated information, clinician access, discreet support, and integrated solutions that address hot flashes, night sweats, vaginal dryness, sexual health, mood, weight management, and fatigue. Employers are responding with menopause-friendly workplace policies, manager training, flexible arrangements, and benefits navigation, particularly where labor participation among midlife women is economically important. These shifts are expanding the role of education, diagnostics, therapeutics, digital platforms, and care navigation while raising the bar for clinical evidence, privacy protection, regulatory compliance, and culturally competent communication.

Cumulative Impact of Artificial Intelligence on Menopause Care, Personalization, and Access

Artificial intelligence is beginning to influence menopause care by improving personalization, access, and clinical decision support, provided it is deployed with appropriate governance and validated data. AI-enabled symptom trackers can help identify patterns in hot flashes, sleep disruption, mood changes, menstrual irregularity, medication adherence, and lifestyle triggers, supporting more informed conversations between patients and clinicians. Natural language tools can also improve health literacy by translating complex guidance into accessible education, although medical oversight remains essential to reduce misinformation risk.

In clinical and research settings, AI can support risk stratification by integrating age, menstrual history, symptom burden, family history, cardiometabolic markers, bone health indicators, medication use, and comorbidities. This may help clinicians identify individuals who need bone density testing, cardiovascular assessment, mental health referral, genitourinary evaluation, or specialist consultation. AI also has potential to improve trial recruitment and real-world evidence generation by identifying underrepresented populations, monitoring patient-reported outcomes, and analyzing longitudinal symptom trajectories.

The cumulative impact of AI will depend on data quality, transparency, bias mitigation, interoperability, and privacy safeguards. Menopause symptoms are influenced by race, ethnicity, socioeconomic status, geography, culture, disability, and prior health experiences; therefore, AI systems trained on narrow datasets may reinforce inequities. Responsible implementation requires clinically validated algorithms, explainable outputs, human-in-the-loop review, consent-based data practices, and inclusive datasets. When these conditions are met, AI can strengthen menopause care pathways, support earlier intervention, and help scale personalized women's health services without replacing clinician judgment.

Key Regional Insights Across Asia-Pacific, Europe, North America, Latin America, Africa, and the Middle East

In Asia-Pacific, menopause care is shaped by rapid population aging, expanding digital health adoption, and diverse cultural attitudes toward reproductive aging. Japan, China, South Korea, Australia, and India face growing demand for midlife women's health services, but care pathways vary widely between advanced specialty networks and regions where stigma, limited clinician training, or out-of-pocket costs constrain access. Traditional medicine, nutrition-led approaches, and family-centered decision-making remain influential in parts of the region, creating opportunities for evidence-based integration and culturally sensitive menopause education.

Europe benefits from structured healthcare systems, active clinical guideline development, and strong public health attention to aging, prevention, and workplace inclusion. Western European countries are advancing menopause recognition in employment policy and clinical pathways, while Eastern and Southern European settings show varied access, reimbursement, and cultural openness. In North America, menopause has strong visibility across clinical practice, telehealth, employer benefits, and consumer education. The United States and Canada have established professional guidance ecosystems and rising demand for personalized care around vasomotor symptoms, genitourinary syndrome of menopause, bone health, and mental wellbeing, although rural, uninsured, underinsured, and minority populations continue to face access gaps.

Latin America is characterized by increasing awareness of women's midlife health, supported by urban healthcare networks and growing use of digital education channels. Brazil and Mexico are important centers of menopause-related demand, yet disparities in specialist access, affordability, and public health coverage influence diagnosis and treatment continuity. In Africa, menopause care remains uneven, with urban centers offering better access than rural regions. Priorities include improving basic awareness, strengthening primary care capacity, addressing stigma, and integrating menopause into broader maternal, reproductive, noncommunicable disease, and aging-related health programs.

The Middle East is seeing rising attention to women's health as healthcare modernization and preventive care initiatives expand, especially in higher-income Gulf states. Cultural sensitivity, privacy, and clinician-led education are central to adoption, particularly for conversations involving sexual health, genitourinary symptoms, mental wellbeing, and hormone therapy. Across all regions, the most effective menopause strategies are those that combine evidence-based care, local cultural understanding, accessible delivery, and long-term prevention.

Key Group Insights Across NATO, G7, BRICS, European Union, ASEAN, and GCC Menopause Care Ecosystems

NATO countries overlap substantially with North American and European healthcare systems, where menopause is increasingly connected to workforce resilience, military family health, occupational wellbeing, and standardized clinical pathways across developed health infrastructures. G7 economies generally have greater access to clinical guidelines, advanced therapeutics, digital health tools, and employer wellbeing programs, though equity gaps persist among rural, low-income, minority, and aging populations. In these high-income policy environments, menopause care is increasingly framed as both a quality-of-life priority and a labor participation issue.

BRICS countries collectively represent highly varied menopause care environments, from advanced urban specialty services to large populations with limited access to trained providers. China, India, Brazil, Russia, and South Africa face distinct healthcare delivery challenges, but all share the need for scalable education, primary care integration, and evidence-based symptom management. The European Union is supported by relatively strong regulatory oversight, health technology assessment processes, and public healthcare infrastructure, although clinical access and reimbursement vary by member state. EU policy attention to gender equality, workforce participation, and healthy aging supports broader recognition of menopause as both a health and workplace issue.

ASEAN countries show rising relevance for menopause care as urbanization, aging, and digital health access increase across Southeast Asia. The region's diversity means care models must account for different languages, income levels, cultural norms, and healthcare financing structures. Public education, community pharmacy engagement, teleconsultation, and primary care training are important levers for improving symptom recognition and appropriate referral. The GCC is positioned around healthcare modernization, women's participation in the workforce, and privacy-centered care delivery. Menopause solutions in this group gain traction when they align with culturally appropriate communication, female clinician access, discreet digital platforms, and preventive health initiatives addressing cardiometabolic and bone health risks.

Key Country Insights Across Major Menopause Markets and Healthcare Systems

China's menopause landscape is influenced by rapid aging, expanding hospital networks, digital health adoption, and increasing attention to chronic disease prevention among midlife women. The United States is one of the most visible menopause care environments, with growing patient advocacy, telehealth adoption, employer benefit integration, and clinician debate around appropriate use of hormonal and nonhormonal therapies. Japan has one of the world's oldest populations, making postmenopausal health, osteoporosis prevention, and quality-of-life management especially relevant. India has a large population entering midlife, but stigma, low awareness, rural access gaps, and competing health priorities make primary care education and culturally appropriate outreach essential.

Germany and France have strong medical infrastructures and preventive health capacity, but patient attitudes toward hormone therapy and complementary approaches can differ. The United Kingdom has made menopause a prominent public and workplace health issue, supported by clinical guidance, media visibility, and employer policy development. Italy and Spain reflect growing interest in healthy aging, sexual health, bone health, and lifestyle-led support, while access pathways depend on regional healthcare organization and specialist availability. Russia faces a combination of urban specialty capacity and regional variation in access, with public education and guideline-based care remaining important priorities.

Australia benefits from structured primary care, professional guidance, and high digital health readiness, while rural and remote access remains a concern. South Korea combines advanced healthcare infrastructure with strong digital engagement, but stigma and work culture may influence symptom disclosure and care-seeking behavior. Canada emphasizes evidence-based care within a publicly funded healthcare context, though geographic distance and specialist availability can affect timely support. Brazil and Mexico show rising awareness through urban healthcare systems and digital education, while affordability, specialist concentration, and uneven public coverage continue to shape patient access.

Actionable Recommendations for Industry Leaders in Menopause Health, Digital Care, and Workplace Wellbeing

Industry leaders should prioritize clinically validated, patient-centered menopause solutions that address the full continuum from perimenopause through postmenopause. This includes education, screening, symptom management, mental health support, genitourinary care, bone health, cardiometabolic risk reduction, and long-term follow-up. Solutions should be designed for shared decision-making, with transparent information on benefits, risks, contraindications, and alternatives.

Organizations should invest in clinician education and multidisciplinary care models involving primary care providers, gynecologists, endocrinologists, pharmacists, mental health professionals, physiotherapists, nutrition specialists, and digital care teams. Building referral pathways and standardized assessment tools can improve early recognition and reduce fragmented care. Employers should adopt menopause-inclusive policies, provide manager training, support flexible work arrangements, and ensure health benefits address evidence-based treatment and counseling.

Digital health developers should validate tools with real-world clinical input, protect sensitive health data, and design for accessibility across age, language, literacy, disability, and cultural contexts. AI-enabled platforms should use representative datasets, explainable models, and escalation protocols for symptoms requiring clinical evaluation. Public and private stakeholders should also invest in awareness campaigns that reduce stigma and correct misinformation, particularly around hormone therapy, nonhormonal options, sexual health, and lifestyle interventions. The most resilient strategies will combine scientific rigor, cultural competence, privacy, affordability, and measurable patient-reported outcomes.

Research Methodology for Evidence-Based Menopause Industry and Healthcare Insights

This executive summary is developed through a structured secondary research methodology focused on verified and evidence-based sources. Inputs include peer-reviewed medical literature, clinical practice guidelines, public health resources, demographic publications, regulatory information, professional society guidance, and government health materials relevant to menopause, perimenopause, postmenopause, vasomotor symptoms, genitourinary syndrome of menopause, bone health, cardiovascular risk, mental wellbeing, and women's health equity.

The methodology applies source triangulation to compare clinical, policy, demographic, and healthcare delivery evidence across regions, groups, and countries. Emphasis is placed on established facts, guideline-consistent interpretation, and observed healthcare trends rather than market sizing, market share, or forecasting. Regional and country insights are synthesized from healthcare infrastructure patterns, population aging dynamics, access conditions, cultural factors, digital health readiness, and public health priorities.

Quality control includes exclusion of unsupported claims, avoidance of promotional statements, and prioritization of current, clinically relevant evidence. Because menopause care evolves with new therapeutics, updated guidelines, and changing public policy, insights should be periodically refreshed to reflect emerging research, regulatory decisions, and real-world outcomes.

Conclusion: Menopause Care Is Evolving Toward Personalized, Preventive, and Inclusive Women's Health

Menopause is becoming a defining area within women's health because it connects symptom relief, preventive medicine, workplace inclusion, healthy aging, and health equity. The landscape is shifting toward personalized care models that recognize differences in symptom burden, clinical risk, culture, access, and patient preference. Hormonal and nonhormonal therapies, lifestyle interventions, digital health tools, mental health support, and genitourinary care all have important roles when guided by evidence and individualized assessment.

Regional and country dynamics show that no single menopause care model fits all healthcare systems. Advanced markets are focused on access quality, employer support, and personalization, while emerging and resource-constrained settings require awareness-building, primary care integration, affordability, and stigma reduction. AI and digital platforms can accelerate access and personalization, but only if designed with clinical validation, privacy protection, and bias mitigation.

For industry leaders, the strongest opportunities lie in trustworthy education, integrated care pathways, inclusive design, and measurable outcomes that improve quality of life for midlife and older women. As menopause becomes more openly discussed and better understood, stakeholders that combine scientific credibility with accessible, culturally competent delivery will be best positioned to support meaningful progress in women's health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Menopause Market, by Product Type

  • 7.1. Introduction
  • 7.2. Hormone Replacement Therapy (HRT)
    • 7.2.1. Combined Estrogen-Progesterone Therapy
    • 7.2.2. Estrogen Therapy
    • 7.2.3. Progesterone Therapy
  • 7.3. Non-Hormonal Treatments
    • 7.3.1. Antidepressants
      • 7.3.1.1. Citalopram
      • 7.3.1.2. Escitalopram
      • 7.3.1.3. Fluoxetine
    • 7.3.2. Botanical Supplements
    • 7.3.3. Gabapentin
    • 7.3.4. Pregabalin

8. Menopause Market, by Stage of Menopause

  • 8.1. Introduction
  • 8.2. Menopause
  • 8.3. Perimenopause
  • 8.4. Postmenopause

9. Menopause Market, by Route of Administration

  • 9.1. Introduction
  • 9.2. Enteral
  • 9.3. Parenteral
  • 9.4. Topical

10. Menopause Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
    • 10.3.1. Company Websites
    • 10.3.2. eCommerce Platforms
  • 10.4. Retail Pharmacies

11. Menopause Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. Europe
  • 11.3. North America
  • 11.4. Latin America
  • 11.5. Africa
  • 11.6. Middle East

12. Menopause Market, by Group

  • 12.1. NATO
  • 12.2. G7
  • 12.3. BRICS
  • 12.4. European Union
  • 12.5. ASEAN
  • 12.6. GCC

13. Menopause Market, by Country

  • 13.1. China
  • 13.2. United States
  • 13.3. Japan
  • 13.4. India
  • 13.5. Germany
  • 13.6. United Kingdom
  • 13.7. Australia
  • 13.8. France
  • 13.9. South Korea
  • 13.10. Italy
  • 13.11. Canada
  • 13.12. Russia
  • 13.13. Brazil
  • 13.14. Mexico
  • 13.15. Spain

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. FPNV Positioning Matrix, 2025
  • 14.3. Market Concentration Analysis, 2025
    • 14.3.1. Concentration Ratio (CR)
    • 14.3.2. Herfindahl Hirschman Index (HHI)
  • 14.4. Recent Developments & Impact Analysis, 2025
  • 14.5. Product Portfolio Analysis, 2025
  • 14.6. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Abbott Laboratories
  • 15.2. Abbvie Inc.
  • 15.3. Amgen Inc.
  • 15.4. Apotex Inc.
  • 15.5. Astellas Pharma Inc.
  • 15.6. AstraZeneca PLC
  • 15.7. Bayer AG
  • 15.8. Cipla Ltd.
  • 15.9. Eli Lilly and Company
  • 15.10. Ferring International Center S.A.
  • 15.11. Fervent Pharmaceuticals, LLC
  • 15.12. Gedeon Richter PLC
  • 15.13. GlaxoSmithKline PLC
  • 15.14. Glenmark Pharmaceuticals Ltd.
  • 15.15. Ipsen Group
  • 15.16. Merck & Co.Inc.
  • 15.17. Mithra Pharmaceuticals S.A.
  • 15.18. Novartis AG
  • 15.19. Novo Nordisk A/S
  • 15.20. Organon & Co
  • 15.21. Pfizer Inc.
  • 15.22. Sun Pharmaceutical Industries Ltd.
  • 15.23. Teva Pharmaceutical Industries Ltd.
  • 15.24. TherapeuticsMD Inc.
  • 15.25. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MENOPAUSE MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL MENOPAUSE MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL MENOPAUSE MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL MENOPAUSE MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL MENOPAUSE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MENOPAUSE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL MENOPAUSE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL MENOPAUSE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL MENOPAUSE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL MENOPAUSE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL MENOPAUSE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL MENOPAUSE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 21. GLOBAL MENOPAUSE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL MENOPAUSE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL MENOPAUSE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HORMONE REPLACEMENT THERAPY (HRT) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HORMONE REPLACEMENT THERAPY (HRT) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HORMONE REPLACEMENT THERAPY (HRT) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMBINED ESTROGEN-PROGESTERONE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COMBINED ESTROGEN-PROGESTERONE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMBINED ESTROGEN-PROGESTERONE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ESTROGEN THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ESTROGEN THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ESTROGEN THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PROGESTERONE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PROGESTERONE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PROGESTERONE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NON-HORMONAL TREATMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NON-HORMONAL TREATMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NON-HORMONAL TREATMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIDEPRESSANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CITALOPRAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CITALOPRAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CITALOPRAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ESCITALOPRAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ESCITALOPRAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ESCITALOPRAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FLUOXETINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FLUOXETINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FLUOXETINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BOTANICAL SUPPLEMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BOTANICAL SUPPLEMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BOTANICAL SUPPLEMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GABAPENTIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GABAPENTIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PREGABALIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PREGABALIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PREGABALIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MENOPAUSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MENOPAUSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MENOPAUSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PERIMENOPAUSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PERIMENOPAUSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PERIMENOPAUSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL POSTMENOPAUSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL POSTMENOPAUSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL POSTMENOPAUSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PARENTERAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PARENTERAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PARENTERAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMPANY WEBSITES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COMPANY WEBSITES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COMPANY WEBSITES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ECOMMERCE PLATFORMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ECOMMERCE PLATFORMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ECOMMERCE PLATFORMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MENOPAUSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC MENOPAUSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE MENOPAUSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA MENOPAUSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA MENOPAUSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA MENOPAUSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST MENOPAUSE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL MENOPAUSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. NATO MENOPAUSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. NATO MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. NATO MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2032 (USD MILLION)
  • TABLE 135. NATO MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 136. NATO MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 137. NATO MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2032 (USD MILLION)
  • TABLE 138. NATO MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. NATO MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. NATO MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 141. G7 MENOPAUSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. G7 MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. G7 MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2032 (USD MILLION)
  • TABLE 144. G7 MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 145. G7 MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 146. G7 MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2032 (USD MILLION)
  • TABLE 147. G7 MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. G7 MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. G7 MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS MENOPAUSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2032 (USD MILLION)
  • TABLE 153. BRICS MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION MENOPAUSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN MENOPAUSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 177. GCC MENOPAUSE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GCC MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. GCC MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2032 (USD MILLION)
  • TABLE 180. GCC MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 181. GCC MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 182. GCC MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2032 (USD MILLION)
  • TABLE 183. GCC MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. GCC MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. GCC MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL MENOPAUSE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA MENOPAUSE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2032 (USD MILLION)
  • TABLE 190. CHINA MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES MENOPAUSE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 205. JAPAN MENOPAUSE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. JAPAN MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. JAPAN MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2032 (USD MILLION)
  • TABLE 208. JAPAN MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 209. JAPAN MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 210. JAPAN MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2032 (USD MILLION)
  • TABLE 211. JAPAN MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 212. JAPAN MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. JAPAN MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 214. INDIA MENOPAUSE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. INDIA MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. INDIA MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2032 (USD MILLION)
  • TABLE 217. INDIA MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 218. INDIA MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 219. INDIA MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2032 (USD MILLION)
  • TABLE 220. INDIA MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. INDIA MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. INDIA MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 223. GERMANY MENOPAUSE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. GERMANY MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. GERMANY MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2032 (USD MILLION)
  • TABLE 226. GERMANY MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 227. GERMANY MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 228. GERMANY MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2032 (USD MILLION)
  • TABLE 229. GERMANY MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. GERMANY MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. GERMANY MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED KINGDOM MENOPAUSE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED KINGDOM MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED KINGDOM MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2032 (USD MILLION)
  • TABLE 235. UNITED KINGDOM MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED KINGDOM MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED KINGDOM MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED KINGDOM MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED KINGDOM MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED KINGDOM MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 241. AUSTRALIA MENOPAUSE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. AUSTRALIA MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. AUSTRALIA MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2032 (USD MILLION)
  • TABLE 244. AUSTRALIA MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 245. AUSTRALIA MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 246. AUSTRALIA MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2032 (USD MILLION)
  • TABLE 247. AUSTRALIA MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. AUSTRALIA MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 249. AUSTRALIA MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 250. FRANCE MENOPAUSE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. FRANCE MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. FRANCE MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2032 (USD MILLION)
  • TABLE 253. FRANCE MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 254. FRANCE MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 255. FRANCE MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2032 (USD MILLION)
  • TABLE 256. FRANCE MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 257. FRANCE MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. FRANCE MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 259. SOUTH KOREA MENOPAUSE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. SOUTH KOREA MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 261. SOUTH KOREA MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2032 (USD MILLION)
  • TABLE 262. SOUTH KOREA MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 263. SOUTH KOREA MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 264. SOUTH KOREA MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2032 (USD MILLION)
  • TABLE 265. SOUTH KOREA MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 266. SOUTH KOREA MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 267. SOUTH KOREA MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 268. ITALY MENOPAUSE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. ITALY MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. ITALY MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2032 (USD MILLION)
  • TABLE 271. ITALY MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 272. ITALY MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 273. ITALY MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2032 (USD MILLION)
  • TABLE 274. ITALY MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 275. ITALY MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 276. ITALY MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 277. CANADA MENOPAUSE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. CANADA MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. CANADA MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2032 (USD MILLION)
  • TABLE 280. CANADA MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 281. CANADA MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 282. CANADA MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2032 (USD MILLION)
  • TABLE 283. CANADA MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 284. CANADA MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 285. CANADA MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 286. RUSSIA MENOPAUSE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. RUSSIA MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. RUSSIA MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2032 (USD MILLION)
  • TABLE 289. RUSSIA MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 290. RUSSIA MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 291. RUSSIA MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2032 (USD MILLION)
  • TABLE 292. RUSSIA MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 293. RUSSIA MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 294. RUSSIA MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 295. BRAZIL MENOPAUSE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. BRAZIL MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. BRAZIL MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2032 (USD MILLION)
  • TABLE 298. BRAZIL MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 299. BRAZIL MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 300. BRAZIL MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2032 (USD MILLION)
  • TABLE 301. BRAZIL MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 302. BRAZIL MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 303. BRAZIL MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 304. MEXICO MENOPAUSE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 305. MEXICO MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. MEXICO MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2032 (USD MILLION)
  • TABLE 307. MEXICO MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 308. MEXICO MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 309. MEXICO MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2032 (USD MILLION)
  • TABLE 310. MEXICO MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 311. MEXICO MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 312. MEXICO MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 313. SPAIN MENOPAUSE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 314. SPAIN MENOPAUSE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. SPAIN MENOPAUSE MARKET SIZE, BY HORMONE REPLACEMENT THERAPY (HRT), 2018-2032 (USD MILLION)
  • TABLE 316. SPAIN MENOPAUSE MARKET SIZE, BY NON-HORMONAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 317. SPAIN MENOPAUSE MARKET SIZE, BY ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 318. SPAIN MENOPAUSE MARKET SIZE, BY STAGE OF MENOPAUSE, 2018-2032 (USD MILLION)
  • TABLE 319. SPAIN MENOPAUSE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 320. SPAIN MENOPAUSE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 321. SPAIN MENOPAUSE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 322. GLOBAL MENOPAUSE MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 323. GLOBAL MENOPAUSE MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025